This article is more than 5 years old. Information may no longer be current.
Tissue plasminogen activator resolves submacular hemorrhage
Click Here to Manage Email Alerts
BOSTON — A tissue plasminogen activator and pneumatic displacement of submacular hemorrhage offered nearly a 90% success rate for patients in a poster presented at the American Society of Retina Specialists meeting.
Colin S. Tan, MBBS, MMed (Ophth), FRCSEd (Ophth) , and colleagues presented the findings of 63 consecutive patients with submacular hemorrhage treated with tissue plasminogen activator (tPA) at a single Singapore institute. Patients received an intravitreal injection of 0.05 mL tPA, followed by 0.3 mL perfluoropropane (C3F8) and strict positioning afterward.
According to the study data, 89.3% of patients had treatment success and 66.1% of patients achieved clinically evident blood displacement. Blood dispersion was seen in 23.2% of patients. Treatment failure, which was described as having neither displacement nor dispersion of the blood, was noted in 10.7% of patients.
Treatment success led to better visual outcomes compared with those with treatment failures. Patients with displaced hemorrhages had the best visual outcomes at final follow-up, compared with those had only hemorrhage dispersion or treatment failure. – by Robert Linnehan
Reference:
Tan CS, et al. Pneumatic displacement of submacular hemorrhage using tissue plasminogen activator. Presented at: American Society of Retina Specialists 35th Annual Meeting, Aug. 11-15, 2017; Boston.
Disclosure: Tan reports he receives travel support from Bayer, Heidelberg Engineering and Novartis. He reports he receives research support from the National Healthcare Group Clinician Scientist Career Scheme Grant.